No differences in antibodies to insulin, GAD65, and IA-2 were observed between treatment and placebo groups at all study visits (supplementary Figure S1, available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc09-0449/DC1).
Chicks are fed mainly on animal food, and when fully grown they may fly with the parents up to 6.4 km (4 mi) to visit supplementary feeding areas.
The dose of corticosteroids was then either maintained stable or reduced in accordance with the protocol recommendations at each visit (supplementary table S4).
The 26-week primary outcome visit was completed by 69 of 74 participants (93%) in the CGM group and 68 of 72 (94%) in the control group, with 5 and 4 participants in the two treatment groups, respectively, discontinuing study participation prior to completion of the 26-week visit (Supplementary Fig. A1).
Data was collected during routine patient care visits, no supplementary interventions were conducted for the analysis presented.
All analyses were performed for the group as a whole and for a subgroup of those participants who reported checking seven or more times per week on at least 90% of visits (see Supplementary Fig. 1 for a flowchart of the number of participants used in each analysis).
It is worth emphasizing that, with the exception of hospital costs, the other components of the health care cost (medical visits and supplementary tests, aside from those due to medications) were significantly higher in subjects with FMS and higher on the whole than that corresponding to drug costs.
To evaluate the effects of the HCCI guidebook, this study conducted an experiment to compare three visiting modes: Visiting with the HCCI guidebook; visiting with a worksheet; and visiting without any supplementary tools.
We are now happy to include this document as part of the Supplementary Material online – please visit the British Journal of Cancer website (http://www.nature.com/bjc).com/bjc
Data were largely complete for central variables (age 96%, sex 94%, date of diagnosis 98%, outcome 99%) but less complete for some supplementary information (country of visit 88%, purpose of travel 71%, country of birth 64%, prophylaxis use 62%).
